The University of Texas MD Anderson Cancer Center and TransCode Therapeutics Inc. form an alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.
Poseida Therapeutics Inc. entered into a collaboration and license agreement with Roche to develop allogeneic CAR T-cell therapies directed to hematologic malignancies.
FDA accepted for review a Biologics License Application from ImmunityBio, Inc. for its antibody cytokine fusion protein as a treatment for patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ with or without Ta or T1 disease.
Merck has paid $35 million Kelun-Biotech to Merck for the exclusive rights to develop, manufacture and commercialize an investigational antibody drug conjugate for treatment of solid tumors.
Mission Bio Inc. has created the first assay capable of determining measurable residual disease in cancer down to the level of individual cells.
FDA has granted Fast Track designation for the development program of eltanexor as monotherapy for the treatment of patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndromes (MDS).
FDA approved crizotinib (Xalkori) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase-positive myofibroblastic tumors.
FDA accepted the Biologics License Application and granted priority review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.
AstraZeneca will acquire TeneoTwo Inc., including its phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma.
FDA approved Breyanzi (lisocabtagene maraleucel), a CD19-directed CAR T-cell therapy, for the treatment of adult patients with large B-cell lymphoma